Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Biogen beat Q4 estimates with a 17% EPS rise and $2.46 billion in sales. The company expects revenue declines in 2025 as multiple sclerosis drug sales drop.

Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.

Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...

CEO Haruo Naito highlighted a 9% year-on-year revenue increase to 601.2 billion yen, with a focus on the pharmaceutical business driving growth. Key contributors included LEQEMBI with a 28.1 billion ...

RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...